Last reviewed · How we verify
Vonoprazan ODT-1 or ODT-2 with Water
Vonoprazan ODT-1 or ODT-2 with Water is a Small molecule drug developed by Phathom Pharmaceuticals, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | Vonoprazan ODT-1 or ODT-2 with Water |
|---|---|
| Sponsor | Phathom Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vonoprazan ODT-1 or ODT-2 with Water CI brief — competitive landscape report
- Vonoprazan ODT-1 or ODT-2 with Water updates RSS · CI watch RSS
- Phathom Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about Vonoprazan ODT-1 or ODT-2 with Water
What is Vonoprazan ODT-1 or ODT-2 with Water?
Vonoprazan ODT-1 or ODT-2 with Water is a Small molecule drug developed by Phathom Pharmaceuticals, Inc..
Who makes Vonoprazan ODT-1 or ODT-2 with Water?
Vonoprazan ODT-1 or ODT-2 with Water is developed by Phathom Pharmaceuticals, Inc. (see full Phathom Pharmaceuticals, Inc. pipeline at /company/phathom-pharmaceuticals-inc).
What development phase is Vonoprazan ODT-1 or ODT-2 with Water in?
Vonoprazan ODT-1 or ODT-2 with Water is in Phase 1.